Zhu Changzhen, Li Yuanxin
Department of Gastrointestinal Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China.
J Int Med Res. 2022 Mar;50(3):3000605221086145. doi: 10.1177/03000605221086145.
Short bowel syndrome (SBS) is a clinical condition characterized by a failure to achieve optimal intestinal adaptation, which is necessary to maintain oral/enteral autonomy. At present, the treatment options for SBS are primarily intestinal replacement and rehabilitation. Intestinal rehabilitation mainly includes non-transplantation surgery and intestinal rehabilitation measures. In recent years, intestinal rehabilitation in patients with SBS using nutritional intestinal hormones, especially glucagon-like peptide-2 analogs, has made great progress. Many high-quality studies have provided evidence-based medical findings to support the development of clinical guidelines. This article reviews the latest research advancements regarding the use of glucagon-like peptide-2 analogs (teduglutide, glepaglutide, and apraglutide) in the treatment of SBS.
短肠综合征（SBS）是一种临床病症，其特征是无法实现最佳肠道适应，而这对于维持经口/肠内自主功能是必要的。目前，SBS的治疗选择主要是肠道替代和康复。肠道康复主要包括非移植手术和肠道康复措施。近年来，使用营养性肠激素，尤其是胰高血糖素样肽-2类似物对SBS患者进行肠道康复取得了很大进展。许多高质量研究提供了循证医学结果以支持临床指南的制定。本文综述了关于使用胰高血糖素样肽-2类似物（替度鲁肽、格列帕鲁肽和阿普拉鲁肽）治疗SBS的最新研究进展。
